Psoriasis
Conditions
Interventions
Sponsors
Peking University People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years (gender is not limited); 2. The diagnosis of mild to moderate stable psoriasis vulgaris must meet: BSA<10%; 3. The subjects fully understand the content of the trial, voluntarily participate in the trial, and have signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who need to receive ultraviolet phototherapy and photochemical therapy during the medication; 2. Those who are known to be allergic to the active ingredients or excipients of the study drug; 3. Patients who are pregnant, breastfeeding, or planning to become pregnant; 4. The researcher believes that it is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psoriasis Area and Severity Index (PASI) Score;Investigator's global assessment (PGA) percentage decline; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in psoriatic skin area (BSA);Patient life quality index (DLQI);European Five-Dimensional Health Scale (EQ-5D-5L); | — |
Countries
China
Contacts
Public ContactShen Juan
Guangdong Zhonghao Pharmaceutical Co., Ltd.
Outcome results
None listed